Introduction
============

According to the American Cancer Society, colorectal cancer (CRC) is currently the third most malignant cancer in the United States among males and females ([@b1-ol-0-0-6572]). In the EU, CRC is the second most common cause of cancer-associated mortality in males, following lung cancer, and the third most frequent cause of cancer-associated mortality in females, following breast and lung cancer ([@b2-ol-0-0-6572]). In Japan, the number of patients with CRC has doubled in the past 20 years to become the second-leading cause of cancer-associated mortality ([@b3-ol-0-0-6572]).

CRC is a heterogeneous disease that occurs via a complex series of molecular events; a number of genes have previously been demonstrated to have a role in the development of the healthy mucosa of the large intestine into a benign tumor, which then transforms into an invasive cancer ([@b4-ol-0-0-6572]).

Previous comprehensive studies of \>13,000 genes have identified 69 genes that are associated with the pathogenesis of CRC ([@b4-ol-0-0-6572]), and detailed analysis has revealed that an average of 9 mutant genes are involved in each case of CRC ([@b5-ol-0-0-6572]). Early CRC detection and the monitoring of patient prognosis are crucial to improve the survival rates of patients with CRC. However, the specimens and array analysis methods reported in previous studies have been problematic for the early diagnosis and monitoring of prognosis, and are not yet suitable for clinical use ([@b4-ol-0-0-6572]--[@b6-ol-0-0-6572]).

The development of microarray technology has facilitated the high-throughput analysis of numerous gene expression patterns ([@b5-ol-0-0-6572],[@b6-ol-0-0-6572]). CRC-specific gene expression profiles have been identified in mRNA ([@b5-ol-0-0-6572],[@b7-ol-0-0-6572]--[@b10-ol-0-0-6572]). Furthermore, the analysis of non-coding RNA, including microRNA (miRNA) and antisense RNA, which cannot serve as templates for direct protein synthesis, has revealed associations between non-coding RNAs and the occurrence of certain types of cancer ([@b11-ol-0-0-6572]--[@b13-ol-0-0-6572]). Our previous studies demonstrated the potential involvement of antisense RNA expression profiles in the development of CRC and hepatic cancer by examining the expression patterns of specific RNAs in cancerous and healthy tissues ([@b14-ol-0-0-6572],[@b15-ol-0-0-6572]).

Blood samples are ideal for detection of certain types of cancer ([@b12-ol-0-0-6572],[@b13-ol-0-0-6572]) and the monitoring of prognosis; therefore, the present study evaluated RNA expression levels in the blood cells of patients, in order to determine their effectiveness in distinguishing cancerous states and healthy states. The current study identified that certain antisense RNA species in blood cells cluster separately in patients with CRC and healthy volunteers, and revealed that one of these RNA species may serve as a biomarker for prognosis.

Materials and methods
=====================

### Patients and blood samples

Blood samples were collected from 6 healthy volunteers and from 28 patients with CRC who underwent surgical resection between April 2006 and March 2009 at Tsukuba University Hospital (Tsukuba, Japan). Blood sampling was periodically conducted up until 12 weeks after surgical resection. None of the patients had received radiotherapy or chemotherapy prior to surgery. The primary clinical characteristics for each patient with CRC involved in the current study are presented in [Table I](#tI-ol-0-0-6572){ref-type="table"}. Informed consent was obtained from all patients for the collection of blood samples and the ethics committee of Tsukuba University Hospital approved the study protocol.

### Total RNA extraction from blood cells

Blood samples were collected from the patients using PAXgene Vacutainer tubes (BD Biosciences, Franklin Lakes, NJ, USA) and subjected to RNA isolation and extraction using a PAXgene Blood RNA Isolation kit (Qiagen, Inc., Valencia, CA, USA), following the manufacturer\'s instructions. The quantity of total RNA obtained was determined using a NanoDrop Spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the 280/260 nm absorbance ratio, and RNA integrity was evaluated using an RNA 6000 Nano LabChip kit (Agilent Technologies, Inc., Santa Clara, CA, USA) and an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.).

### Microarray analysis

Cyanine 3 (Cy3)-labeled cDNA was synthesized from 10 µg total RNA extracted from the blood samples using a LabelStar Array kit (Qiagen, Inc.) with Cy3-dUTP (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and random nonamer primers. The labeled cDNA was hybridized with probe sequences on an Agilent 44 Kx4 human sense and antisense custom microarray slide (Agilent Technologies, Inc.) ([@b16-ol-0-0-6572]) in a hybridization solution prepared with an *In Situ* Hybridization Plus kit (Agilent Technologies, Inc.), according to the manufacturer\'s instructions. The Cy3 fluorescence signals were imaged using an Agilent C DNA microarray scanner (Agilent Technologies, Inc.) and processed using the Feature Extraction version 8.1 software (Agilent Technologies, Inc.).

### Statistical analysis

The microarray data were processed using the GeneSpring GX version 12 software (Agilent Technologies, Inc.) to perform the log transformations and the normalization of all values to the 75th percentile of the respective microarray, followed by normalization to the respective median expression level for all samples. Additionally, the normalized gene expression data were filtered on flags following the protocol of the manufacturer GeneSpring GX (<http://www.chem.agilent.com/cag/bsp/products/gsgx/manuals/GeneSpring-manual.pdf>). Only those genes classified as flag-present or flag-marginal in \>70% of all the array samples, were allowed to pass the filter. The expression profiles of the RNA samples were analysed, using GeneSpring GX version 12 software, with unpaired t-tests, with Benjamini-Hochberg false discovery rate correction ([@b17-ol-0-0-6572]) for unequal variances, as described in the results section. P\<0.05 was considered to indicate a statistically significant difference.

Two-dimensional hierarchical clustering based on Euclidean distance measures was performed using Ward\'s method ([@b18-ol-0-0-6572]). The data were visualized using heat maps and dendrograms, as described previously ([@b14-ol-0-0-6572]). Sample trees were drawn horizontally and gene trees were drawn vertically. Principal component analysis (PCA) was used to identify and characterize trends in multigene expression profiles.

Results
=======

### RNA quality

The quality of the RNAs obtained from the blood samples of the healthy volunteers and patients with CRC were initially examined using a NanoDrop Spectrophotometer at an absorbance ratio of 280/260 nm, revealing that the ratios were between 1.8 and 2.0. These results indicated that the total RNAs prepared were usable for labeling with Cy3-dUTP and subsequent microarray analysis. The integrity of the RNAs was then examined using an Agilent 2100 Bioanalyzer, revealing that the Rin values of the RNA samples ranged from 5.9 to 9.2. As the random priming method was utilized for the synthesis of Cy3-labeled cDNAs from the RNA samples, the lower Rin values were considered not to affect the quality of the cDNAs for analysis.

### Microarray analysis

Cy3-labeled cDNAs were synthesized from the extracted RNA and subjected to microarray analysis. A total of 40 transcripts were identified as differentially expressed with a magnitude of \>2-fold (P\<0.05) between the CRC blood cells and non-cancerous blood cells; of these transcripts, 20 were sense sequences and 20 were antisense sequences ([Table II](#tII-ol-0-0-6572){ref-type="table"}). According to the cluster analysis, CRC and non-cancerous blood samples were revealed to form separate clusters for the antisense transcripts, but not to form separate clusters for the sense transcripts ([Fig. 1](#f1-ol-0-0-6572){ref-type="fig"}; the clustering data for the sense transcripts are not presented).

### PCA for 28 patients with CRC using 20 antisense transcripts

As presented in [Fig. 2](#f2-ol-0-0-6572){ref-type="fig"}, PCA analysis revealed that the CRC and non-cancerous blood samples were well separated with the first principal component; its contribution rate was \~43.5%. The contribution rates of the second and third principal components were calculated to be \~7.7% and \~6.4%, respectively. These results indicate that the CRC and non-cancerous blood samples were effectively separated with only the first component.

### Hierarchical cluster analysis of patients with stage I or II CRC

The results of the microarray with RNA samples from patients with stage I and II CRC and controls revealed a total of 72 transcripts that were significantly differentially expressed with a magnitude of \>2-fold (P\<0.01) between the blood cells of healthy volunteers and of patients with CRC. A total of 33 transcripts were sense sequences and 39 were antisense sequences ([Table III](#tIII-ol-0-0-6572){ref-type="table"}). When the blood samples from patients with stage I or II CRC and healthy volunteers were subjected to cluster analysis for the aforementioned sense and antisense transcripts, the patients were observed to form respective clusters only with antisense transcripts ([Fig. 3](#f3-ol-0-0-6572){ref-type="fig"}; the clustering data for the sense transcripts are not presented).

### PCA with stage I or II CRC using 39 antisense transcripts

The 39 antisense transcripts were further examined using PCA analysis. As presented in [Fig. 4](#f4-ol-0-0-6572){ref-type="fig"}, CRC and non-cancerous RNA samples were revealed to be well separated with regard to the first principal component; its contribution rate was \~43.5%. The contribution rates of the second and third principal components were calculated to be \~7.9% and \~7.0%, respectively. These results indicate that the patients with stage I or II CRC were effectively separated from healthy volunteers with the first component.

### Comparison of HDHD1 antisense transcript expression levels

The antisense transcript of haloacid dehalogenase-like hydrolase 1 domain-containing (HDHD1), which was the highest and third highest differentially expressed transcript in the earlier analyses ([Tables II](#tII-ol-0-0-6572){ref-type="table"} and [III](#tIII-ol-0-0-6572){ref-type="table"}, respectively), was selected for evaluation at various time points following the surgical resection of tumor tissues from patients with CRC. The expression levels of the HDHD1 antisense transcript at 1 week and at 3 months post-surgery were decreased approximately to the expression levels observed in healthy volunteers ([Fig. 5](#f5-ol-0-0-6572){ref-type="fig"}). The results suggest that certain antisense transcripts, including HDHD1, may serve as potential biomarkers of CRC diagnosis and prognosis.

Discussion
==========

Previous studies have identified the potential involvement of antisense RNA expression in the development of colorectal and hepatic cancers by examining RNA expression patterns in cancerous and healthy tissues ([@b14-ol-0-0-6572],[@b15-ol-0-0-6572]). However, the functions and underlying mechanisms of antisense transcripts in colorectal and hepatic cancers have yet to be elucidated. The present study examined the association between the expression levels of certain RNA transcripts in blood cells and the occurrence of CRC, and the subsequent changes in the transcript amount following the removal of cancerous tissues in patients. The examinations revealed that antisense transcripts of up to 39 genes demonstrated a clear association between their expression levels in blood cells and the occurrence of CRC; following tumor resection in patients with CRC, the expression levels of the HDHD1 antisense transcript were decreased to approximately the levels observed in healthy volunteers, suggesting that these antisense transcripts are involved in the generation and maintenance of CRC. Furthermore, the antisense transcripts may serve as diagnostic markers for CRC occurrence, and certain antisense transcripts, including HDHD1, may be potential prognostic markers for CRC.

The early detection of CRC significantly improves patient prognosis and is essential in reducing CRC-associated mortality ([@b19-ol-0-0-6572]) Patients with CRC often present with an advanced stage disease and concomitant poor prognosis ([@b1-ol-0-0-6572]). The best known serum biomarkers, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), are not recommended for clinical screening due to limited specificity and sensitivity ([@b20-ol-0-0-6572]). A number of circulating proteins have previously been indicated to be diagnostically useful; however, none of these proteins has individually demonstrated sufficient sensitivity or specificity to be used in clinical practice ([@b20-ol-0-0-6572]).

In our previous study, the expression levels of certain antisense transcripts in CRC tissues were revealed to significantly differ from their corresponding normal tissues ([@b14-ol-0-0-6572]), indicating that those specific antisense transcripts may be involved in the generation and maintenance of CRC tumor tissues. The antisense transcripts in CRC tissues are distinct from those identified in the present study of patients with CRC. Further studies are required to determine the functional association between the antisense transcripts revealed in our previous study and those in the present study.

Previous studies have indicated that certain antisense transcripts are involved in mRNA stabilization ([@b21-ol-0-0-6572]), the suppression of mRNA synthesis ([@b22-ol-0-0-6572],[@b23-ol-0-0-6572]), miRNA functions ([@b24-ol-0-0-6572]) and the promotion of protein synthesis ([@b25-ol-0-0-6572]). Therefore, antisense transcripts have various functions, each of which may be specific to the respective antisense transcript species. Although the functions of non-coding RNA, antisense RNA and miRNA in tumorigenesis require further study, it is possible that the various antisense transcripts demonstrated in the present study may serve as potential biomarkers for CRC diagnosis and prognosis. In the future, the mechanisms underlying the differences in expression levels of the antisense transcripts should be investigated extensively to understand their involvement in CRC generation.
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###### 

Clinical characteristics of patients with colorectal cancer evaluated using microarray analysis (n=28).

  Variable                             Value
  ------------------------------------ -------------
  Gender, n                            
    Male                               21
    Female                               7
    Median age (range), years          60 (37--86)
  Tumor location, n                    
    Colon                              14
    Rectum                             14
  AJCC stage, n                        
    I                                    9
    II                                   9
    III                                  6
    IV                                   4
  Other samples, n                     
    1 week post-surgery samples          4
    3 months post-surgery samples        8
    Volunteers (non-cancer patients)     6

AJCC, American Joint Committee on Cancer.

###### 

Top 20 antisense transcripts differentially regulated between blood cells from patients with colorectal cancer and healthy volunteers.

  Accession number   Gene symbol   Gene name                                                                 Fold-change
  ------------------ ------------- ------------------------------------------------------------------------- -------------
  NM_012080          HDHD1         Haloacid dehalogenase-like hydrolase domain-containing 1                  5.68
  NM_005824          LRRC17        Leucine-rich repeat containing 17                                         4.38
  XR_016125          LOC642337     Similar to hCG1648021                                                     3.40
  NM_016630          SPG21         Spastic paraplegia 21                                                     2.71
  XM_001132492       LOC732276     Hypothetical protein LOC732276                                            2.54
  NM_175611          GRIK1         Glutamate receptor, ionotropic, kainate 1                                 2.54
  NM_003290          TPM4          Tropomyosin 4                                                             2.40
  NM_006516          SLC2A1        Solute carrier family 2, member 1                                         2.39
  NM_015317          PUM2          Pumilio homolog 2                                                         2.36
  NM_024494          WNT2B         Wingless-type MMTV integration site family, member 2B                     −2.35
  NM_025140          CCDC92        Coiled-coil domain-containing 92                                          2.31
  NM_001037738       NPM1          Nucleophosmin 1                                                           2.31
  NM_024860          SETD6         SET domain-containing 6                                                   2.27
  NM_020179          SMCO4         Homo sapiens chromosome 11 open reading frame 75 (C11orf75)               2.25
  XR_016982          LOC645280     Hypothetical LOC645280                                                    2.21
  NM_025225          PNPLA3        Homo sapiens patatin-like phospholipase domain-containing 3               2.20
  NM_021975          RELA          Homo sapiens v-rel avian reticuloendotheliosis viral oncogene homolog A   2.03
  XM_926307          LOC642927     Similar to COLlagen family member (col-36)                                2.02
  NM_172249          CSF2RA        Homo sapiens colony stimulating factor 2 receptor, alpha, low-affinity    2.02
  NM_005206          CPK           Homo sapiens v-crk avian sarcoma virus CT10 oncogene homolog              2.00

###### 

Top 39 antisense transcripts differentially regulated between blood cells from patients with stage I/II colorectal cancer and healthy volunteers.

  Accession number   Gene symbol   Gene name                                                                                 Fold-change
  ------------------ ------------- ----------------------------------------------------------------------------------------- -------------
  XM_001132487.1ea   LOC732271     Hypothetical protein LOC732271                                                            6.24
  NM_005824.1ea      LRRC17        Leucine-rich repeat-containing 17                                                         4.50
  NM_012080.3ea      HDHD1         Haloacid dehalogenase-like hydrolase domain-containing 1                                  3.57
  NM_024422.2ia      DSC2          Desmocollin 2                                                                             2.94
  NM_174913.1ia      NOP9          NOP9 nucleolar protein                                                                    2.92
  NM_016630.3ia      SPG21         Spastic paraplegia 21                                                                     2.71
  NM_024494.1ia      WNT2B         Wingless-type MMTV integration site family, member 2B                                     2.61
  NM_175611.2ea      GRIK1         Glutamate receptor, ionotropic, kainate 1                                                 2.54
  NM_014578.2ia      RHOD          Ras homolog family member D                                                               2.54
  NM_006296.3ia      VRK2          Vaccinia-related kinase 2                                                                 2.47
  NM_139284.1ia      LGI4          Leucine-rich repeat LGI family                                                            2.44
  NM_001315.1ia      MAPK14        Mitogen-activated protein kinase 14                                                       2.40
  XR_016125.1ea      LOC642337     Similar to hCG1648021                                                                     2.39
  NM_005618.2ia      DLL1          Felta-like 1 (Drosophila)                                                                 2.37
  XM_001132492.1ea   LOC732276     Hypothetical protein LOC732276                                                            2.36
  NM_025225.2ia      PNPLA3        Patatin-like phospholipase domain-containing 3                                            2.31
  NM_171846.1ea      LACTB         Lactamase, β                                                                              2.31
  NR_002162.1ea      ATP5EP2       Synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit pseudogene 2         2.29
  XM_001125928.1ea   LOC283804     Similar to testicular metalloprotease-like, disintegrin-like, Cysteine-rich protein Iva   2.25
  XM_001129971.1ea   LOC729333     Hypothetical protein LOC729333                                                            2.23
  NM_212554.2ia      METTL10       Methyltransferase-like 10                                                                 2.22
  NM_006516.1ia      SLC2A1        Solute carrier family 2, member 1                                                         2.20
  NM_015317.1ia      PUM2          Pumilio homolog 2                                                                         2.18
  XM_293121.4ea      C20orf66      Chromosome 20 open reading frame 66                                                       2.15
  NM_003290.1ia      TPM4          Tropomyosin 4                                                                             2.12
  XR_016982.1ea      LOC645280     Hypothetical LOC645280                                                                    2.12
  XR_018204.1ea      LOC647757     Similar to tetratricopeptide repeat protein 4 (TPR repeat protein 4)                      2.09
  NM_006708.1ia      GLO1          Glyoxalase I                                                                              2.08
  NM_020179.1ia      SMCO4         Single-pass membrane protein with coiled-coil domains 4                                   2.06
  NM_001010898.1ia   SLC6A17       Solute carrier family 6 (neutral amino acid transporter), member 17                       2.06
  NM_004423.3ia      DVL3          Dishevelled segment polarity protein 3                                                    2.05
  NM_001093.2ia      ACACB         Acetyl-CoA carboxylase β                                                                  2.04
  NM_005751.3ia      AKAP9         A kinase (PRKA) anchor protein 9                                                          2.04
  NM_025140.1ia      CCDC92        Coiled-coil domain-containing 92                                                          2.04
  NM_017440.2ia      MDM1          Mdm1 nuclear protein homolog (mouse)                                                      2.04
  NM_000637.2ia      GSR           Glutathione reductase                                                                     2.03
  NM_080588.1ia      PTPN7         Protein tyrosine phosphatase, non-receptor type 7                                         2.02
  NM_024860.1ia      SETD6         SET domain-containing 6                                                                   2.01
  NM_005206.3ia      CRK           V-crk avian sarcoma virus CT10 oncogene homolog                                           2.01
